About the Consortium

Who We Are

The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.


The MCDC is currently recruiting a broad and diverse group of interested parties that includes representatives from large businesses, small businesses, traditional and non-traditional government contractors, academic research institutions, and not-for-profit organizations with collective expertise in the technology areas specifically related to the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) mission.


NOTICE: Name Change

The National Chemical & Biological Defense Consortium is now the Medical CBRN Defense Consortium (MCDC). While we feel the new name and logo better reflect the technology areas specific to the medical countermeasures Other Transaction Agreement, nothing else about the consortium is changing. Over the next few months you will be able to connect with us using either the new email addresses and website URL or the old.


See Our Leadership

Leadership

Ronald K. Poropatich, M.D.
University of Pittsburgh
Formation Committee, Chair

Dr. Poropatich is the Executive Director of the Center for Military Medicine Research, Health Sciences at the University of Pittsburgh and served as the Deputy Director of the US Army’s Telemedicine and Advanced Technology Research Center. Dr. Poropatich received his medical degree from Drexel University, completed a residency and internship at the Walter Reed Army Medical Center, and is a diplomate of the American Board of Internal Medicine in Medicine, Pulmonary and Critical Care Medicine, a Fellow of the American College of Physicians, Chest Physicians, and Fellow and past president of the American Telemedicine Association.

Michael G. MacNaughton, Ph.D.
Southwest Research Institute
Formation Committee, Vice-Chair

Dr. MacNaughton is the Vice President of the Chemistry & Chemical Engineering Division of the Southwest Research Institute. For over 40 years, Dr. MacNaughton has been active in multidisciplinary engineering and chemistry research programs. He provides management leadership for programs in chemical and biological warfare defense environmental engineering, and analytical chemistry. A retired U.S. Air Force Colonel, Dr. MacNaughton has a Ph.D. in Environmental Engineering from Stanford University, a M.S. in Environmental Engineering from the University of Michigan, and a B.S. in Civil Engineering from Michigan State University.

M. Javad Aman, Ph.D.
Integrated BioTherapeutics
Formation Committee

Dr. Aman is the President and Chief Scientific Officer of Integrated BioTherapeutics, Inc., a biotechnology company focused on emerging infectious diseases and biodefense therapeutics. He worked as a lead scientist at the USAMRIID, where his research resulted in development of a vaccine for Ebola and Marburg viruses, now in late pre-clinical development. He also leads a DTRA funded effort for development of pan-ebolavirus therapeutic antibodies. Dr. Aman has also developed antibodies and vaccines for several bacterial toxins including an SEB vaccine currently in clinical development. He serves as Principal Investigator on multiple government funded contracts and grants, has authored over 90 publications in international journals and is the inventor on multiple U.S. and international patents and patent applications. Dr. Aman received his Ph.D. in molecular immunology at the University of Mainz, Germany, completed a research fellowship at the National Institutes of Health, and served as a faculty at the University of Virginia before joining USAMRIID.

Robert V. House, Ph.D., FATS
Nanotherapeutics
Formation Committee

Dr. House is the Senior Vice President, Government Contracts at Nanotherapeutics. Dr. House has nearly 30 years of experience in basic and applied biomedical research and development, specializing in the assessment of inadvertent and therapeutic immunomodulation. Dr. House earned his B.A. in Zoology, M.S. in Public Health and Ph.D. from the University of North Carolina. He is the author, co-author or editor of more than 100 articles and books, is an Adjunct Professor at George Mason University where he teaches medical countermeasure development.

Brennan Klose
AbViro, LLC
Formation Committee

Brennan Klose is a Managing Partner at AbViro, LLC., a biotechnology firm in Bethesda, Maryland, and the Executive Chairman of the Innovation Financing Roundtable, an organization dedicated to developing solutions to combine and leverage government and private-sector funds to accelerate R&D in the 21st century financial ecosystem. Mr. Klose earned a B.A. in Geological Sciences from Harvard University, has a number of publications in planetary geology and virology, and holds patents in antiviral therapeutics.

Jan A. Van Prooyen, Ph.D.
Verndari Inc.
Formation Committee

Dr. Van Prooyen’s thirty-year Army career included leadership assignments focused on the acquisition of major defense systems, chemical-biological defense technology, missile defense technology programs, nuclear weapons, and developmental testing. He retired as a Major General and then served as President, Bechtel Defense and Space, with projects including eliminating chemical weapons in the U.S., constructing missile defense silos in Alaska, and managing biological weapons proliferation prevention programs in central Asia. He earned his B.S. from the United States Military Academy, M.S. in nuclear Engineering from the University of Arizona, and Ph.D. in nuclear engineering from the University of Virginia. He served as Deputy Laboratory Director of the Los Alamos National Laboratory from 2006 to 2009.

Brian Price, Ph.D.
Battelle
Formation Committee

Dr. Price is the Director of Business Development for Battelle’s Life Sciences Research Business, which specializes in toxicology and pharmacology services for multiple HHS agencies, commercial pharmaceutical and tobacco clients. He is responsible for building relationships with both Government and commercial clients and supporting the strategic development of new capabilities and service offerings at Battelle. Dr. Price has over 15 years of experience in basic and applied biomedical research and development, specializing in vaccine development and characterization. Dr. Price earned his Ph.D. from the Department of Microbiology at The Ohio State University.

Mike Stebbins, Ph.D.
Advanced Technology International
Consortium Management Firm

Dr. Stebbins is the Director of Operations with Advanced Technology International (ATI) and serves as Consortium Manager for the Medical CBRN Defense Consortium (MCDC) for which ATI serves as the Consortium Management Firm. Throughout his 9+ year tenure at ATI, Dr. Stebbins has served as the Director of Business Planning and Development where he led the capture and startup of the $70M, 5-year UI LABS-led Digital Manufacturing and Design Innovation Institute (DMDII), one of several National Network for Manufacturing Innovation (NNMI) institutes solicited by DoD. Dr. Stebbins also had significant roles on ATI-led programs looking at the epidemiological effects of exposure to the vanadium manufacturing process as well as demonstrating and validating the impact of copper on reducing levels of harmful microbes. Prior to ATI Dr. Stebbins worked in the industrial chemical, environmental testing and pharmaceuticals industries. Dr. Stebbins earned his Ph.D. in analytical chemistry from the University of Tennessee, Knoxville and his B.S. in chemistry from the College of Charleston.

Mica Dolan, CPCM
Advanced Technology International
Consortium Management Firm

Mrs. Dolan is a Corporate Manager supporting Advanced Technology International (ATI) and is a Certified Professional Contracts Manager (CPCM). She currently serves as the Contractual Team Lead for the Innovative Prototypes division, including the multi-billion dollar Department of Defense Ordnance Technology Consortium (DOTC) program, the Vertical Lift Consortium (VLC) and the National Spectrum Consortium. Her current duties now include the MCDC. ATI serves as the Consortium Management Firm for all of these. As the Contractual Team Lead for these efforts, Mrs. Dolan is responsible for overseeing all solicitation development, cost proposal analysis, proposal preparation and contracting under these programs including preparing, administering, negotiating and monitoring various types of contracts; pre-award and post award activities in support of ATI programs; the preparing of ATI cost proposals; monitoring contract budgets; and preparation of closeout documents. Mrs. Dolan was awarded her Masters Degree in Business Administration from the Citadel and her Bachelor of Science in Finance and Human Resources Management with a minor in French from the University of South Carolina.